A single intravenous infusion of Lilly's investigational base editor VERVE‑102 produced dose-dependent reductions in PCSK9 of up to 88 per cent and LDL cholesterol of up to 62 per cent, with effects sustained for up to 18 months. …
Single infusion of Lilly gene editing cuts cholesterol with the company planning long-term study
May 27, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News